References
- 1. Gaieski, David, Edwards, Kallan, Michael, Carr, Brendan, MD, MA. Benchmarking the Incidence and Mortality of Severe Sepsis in the United States*. Crit Care Med. 2013; 41(5):1167-1174. doi: 10.1097/CCM.0b013 e31827c09f8.
- 2. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med 2016; 193(3): 259-72.10.1164/rccm.201504-0781OC26414292
- 3. Stevenson EK, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014;42(3):625–3110.1097/CCM.0000000000000026431393024201173
- 4. Lagu T, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40(3):754–6110.1097/CCM.0b013e318232db6521963582
- 5. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014; 5(1):4–1110.4161/viru.27372391638224335434
- 6. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–1010.1001/jama.2016.0287496857426903338
- 7. Dogaru, S., Teusdea, C., & Purcaru, F. (2020). Risk Stratification in Sepsis: What We Can Do in the Emergency Room?, Internal Medicine, 17(3), 37-42. doi: https://doi.org/10.2478/inmed-2020-011510.2478/inmed-2020-0115
- 8. Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP, 2017
- 9. APA Shapiro, Nathan I. MD; Wolfe, Richard E. MD; Moore, Richard B. MD; Smith, Eric BA; Burdick, Elizabeth PhD; Bates, David W. MD, MSc Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule*, Critical Care Medicine: March 2003 - Volume 31 - Issue 3 - p 670-675 doi: 10.1097/01.CCM.0000054867.01688.D110.1097/01.CCM.0000054867.01688.D112626967
- 10. Bomberg H, Volk T, Groesdonk HV, et al. Presepsin (sCD14-ST) Is a Novel Marker for Risk Stratification in Cardiac Surgery Patients. Anesthesiology. 2017. doi:10.1097/ALN.000000000000152210.1097/ALN.000000000000152228099244
- 11. Erenler AK, Yardan T. Presepsin (sCD14-ST) as a biomarker of sepsis in clinical practice and in emergency department: A mini review. LaboratoriumsMedizin. 2015. doi:10.1515/labmed-2015-007210.1515/labmed-2015-0072
- 12. Behnes M, Lepiorz D, Lang S, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014. doi: 10.1186/s13054-014-0507-z10.1186/s13054-014-0507-z417428325190134
- 13. Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis. PLoS One. 2018;13(1). doi:10.1371/journal.pone.019148610.1371/journal.pone.0191486578338029364941
- 14. Marshall, J.C. The staging of sepsis: understanding heterogeneity in treatment efficacy. Crit Care 9, 626 (2005). https://doi.org/10.1186/cc390710.1186/cc3907141400916356249
- 15. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. Am J Respir Crit Care Med. 2015; 192(9):1045-1051. doi:10.1164/rccm.201411-2125CP10.1164/rccm.201411-2125CP464219926177009